활동성 특발성 염증성 근육병증이 있는 피험자에서 CABA-201의 안전성과 효능을 평가하기 위한 공개 라벨 연구
활동성 특발성 염증성 근육병증 환자를 대상으로 자가 CD19 특이적 키메라 항원 수용체 T 세포(CABA-201)의 안전성과 효능을 평가하기 위한 1/2상 공개 라벨 연구
RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Idiopathic inflammatory myopathies (IIMs, or myositis) are a group of rare autoimmune diseases characterized by inflammation and muscle weakness. Though the cause of IIM is not well understood, some subtypes of IIM, including dermatomyositis (DM), anti-synthetase syndrome (ASyS), immune-mediated necrotizing myopathy (IMNM), and juvenile idiopathic inflammatory myopathy (JIIM), are thought to involve B cells that cause the body to attack different tissues in the body. This study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, that can be given to patients with DM, ASyS, IMNM, or JIIM who have active disease. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
- 3단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Cabaletta Bio
- 전화번호: 4444 267-759-3100
- 이메일: clinicaltrials@cabalettabio.com
연구 장소
-
-
-
Göttingen, 독일, 37075
- 아직 모집하지 않음
- Universitätsmedizin Göttingen - Accepting Adult Patients
-
연락하다:
- Dr. Jana Zschüntzsch
- 이메일: j.zschuentzsch@med.uni-goettingen.de
-
수석 연구원:
- Dr. Jana Zschüntzsch
-
-
-
-
California
-
Orange, California, 미국, 92868
- 모병
- University of California Irvine - Accepting Adult Patients
-
수석 연구원:
- Tahseen Mozaffar, MD
-
연락하다:
- Alpha Clinic
- 전화번호: 949-824-3990
- 이메일: alphaclinic@uci.edu
-
San Francisco, California, 미국, 94158
- 모병
- University of California, San Francisco Benioff Children's Hospital - Accepting Young Adult and Juvenile Patients
-
연락하다:
- Zilan Zheng
- 전화번호: 415-353-1301
- 이메일: Zilan.Zheng@ucsf.edu
-
수석 연구원:
- Susan Kim, MD, MMSc
-
-
Colorado
-
Aurora, Colorado, 미국, 80046
- 모병
- Children's Hospital Colorado - Accepting Juvenile Patients
-
수석 연구원:
- Dr. Kentaro Yomogida, MD
-
연락하다:
- Callie Strini - Primary Clinical Research Coordinator
- 전화번호: 720-777-9845
- 이메일: callie.strini@childrenscolorado.org
-
-
Florida
-
Jacksonville, Florida, 미국, 32224
- 모병
- Mayo Clinic Florida - Accepting Adult Patients
-
연락하다:
- Gabrielle Pariseau
- 전화번호: 904-953-5549
- 이메일: pariseau.gabrielle@mayo.edu
-
St. Petersburg, Florida, 미국, 33701
- 모병
- Johns Hopkins All Children's Hospital - Accepting Juvenile Patients
-
수석 연구원:
- Natalie Booth, DO
-
연락하다:
- Laura Escobar
- 전화번호: 727-767-2946
- 이메일: llabarr2@jh.edu
-
-
Georgia
-
Atlanta, Georgia, 미국, 30032
- 모병
- Emory University - Accepting Adult Patients
-
연락하다:
- John Varghese
- 이메일: john.varghese@emory.edu
-
수석 연구원:
- Prateek Chandrashekar Gandiga, MD, FACP
-
Atlanta, Georgia, 미국, 30029
- 모병
- Children's Healthcare of Atlanta - Accepting Juvenile Patients
-
수석 연구원:
- Shanmuganathan Chandrakasan, MD
-
연락하다:
- Judson Russell
- 전화번호: 404-785-7263
- 이메일: Judson.russell@choa.org
-
-
Illinois
-
Chicago, Illinois, 미국, 60611
- 모병
- Northwestern Memorial Hospital - Accepting Adult Patients
-
수석 연구원:
- Dr. George Georges, MD
-
연락하다:
- Kaitlin King
- 전화번호: 312-695-0990
- 이메일: autoimmunesct@nm.org
-
Chicago, Illinois, 미국, 60637
- 모병
- The University of Chicago Medical Center - Accepting Adult and Juvenile Patients
-
수석 연구원:
- Dr. Iazsmin Ventura, MD
-
연락하다:
- Dr. Iazsmin Ventura, MD - Adult patient contact
- 전화번호: 773-702-6619
- 이메일: iventura@uchicago.edu; Dequana.jones@bsd.uchicago.edu
-
부수사관:
- Dr. Cuoghi Edens, MD, FAAP
-
연락하다:
- Dr. Cuoghi Edens, MD, FAAP - Juvenile patient contact
- 이메일: cedens@bsd.uchicago.edu; Sydni.Hill@bsd.uchicago.edu
-
Chicago, Illinois, 미국, 60611
- 모병
- Ann & Robert H. Lurie Children's Hospital of Chicago - Accepting Young Adult and Juvenile Patients
-
연락하다:
- Tyler Sorensen
- 전화번호: 312-277-6828
- 이메일: tsorensen@luriechildrens.org
-
수석 연구원:
- Pooja N. Patel, DO
-
-
Kansas
-
Kansas City, Kansas, 미국, 66160
- 모병
- University of Kansas Medical Center - Accepting Adult Patients
-
연락하다:
- Samantha Colgan
- 전화번호: 913-945-9938
- 이메일: scolgan@kumc.edu
-
-
Maryland
-
Bethesda, Maryland, 미국, 20892
- 모병
- National Institutes of Health - Accepting Adult and Juvenile Patients
-
연락하다:
- Julie Thompson
- 전화번호: 301-480-3191
- 이메일: Julie.thompson@nih.gov
-
수석 연구원:
- Andrew Mammen, M.D., Ph.D.
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02115
- 모병
- Boston Children's Hospital - Accepting Young Adults and Juvenile Patients
-
수석 연구원:
- Susan Prockop, MD
-
연락하다:
- Kyle McBrearty
- 전화번호: 617-355-2780
- 이메일: kyle.mcbrearty@childrens.harvard.edu
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48105
- 모병
- University of Michigan - Accepting Young Adult and Juvenile Patients
-
연락하다:
- Abigail Whalen
- 전화번호: 734-615-4466
- 이메일: abigaiwh@med.umich.edu
-
수석 연구원:
- Dr. Jennifer Agrusa, MD
-
-
Minnesota
-
Rochester, Minnesota, 미국, 55902
- 모병
- Mayo Clinic - Accepting Adult Patients
-
연락하다:
- Bridget Neja
- 전화번호: 507-266-9150
- 이메일: neja.bridget@mayo.edu
-
-
New York
-
New York, New York, 미국, 10021
- 모병
- Hospital for Special Surgery - Accepting Adult and Juvenile Patients
-
연락하다:
- Janvi Bhatia
- 전화번호: 212-774-2123
- 이메일: bhatiaj@hss.edu
-
수석 연구원:
- David R. Fernandez, MD, PhD
-
New York, New York, 미국, 10021
- 모병
- Memorial Sloan Kettering Cancer Center - Accepting Adult and Juvenile Patients
-
수석 연구원:
- Jae Park, MD
-
연락하다:
- Atifah Osrat
- 전화번호: 646-608-2091
- 이메일: osrata1@mskcc.org
-
The Bronx, New York, 미국, 10467
- 모병
- Children's Hospital at Montefiore - Accepting Young Adult and Juvenile Patients
-
연락하다:
- Emily Gillies
- 전화번호: 718-696-2402
- 이메일: egillies@montefiore.org
-
수석 연구원:
- Dr. Dawn Wahezi, MD, MS
-
-
North Carolina
-
Chapel Hill, North Carolina, 미국, 27599
- 모병
- University of North Carolina at Chapel Hill - Accepting Adult Patients
-
수석 연구원:
- Saira Sheikh, MD
-
연락하다:
- Leah Luizza
- 이메일: leah.luizza@med.unc.edu
-
Durham, North Carolina, 미국, 27710
- 모병
- Duke University Medical Center - Accepting Young Adults and Juvenile Patients
-
수석 연구원:
- Kaveh Ardalan, MD, MS
-
연락하다:
- Lynn Rodgers, MS
- 전화번호: 919-668-2953
- 이메일: Lynn.rodgers@duke.edu
-
-
Oregon
-
Portland, Oregon, 미국, 97239
- 모병
- Oregon Health & Science University - Accepting Adult Patients
-
연락하다:
- Katie Lewis
- 전화번호: 503-908-9724
- 이메일: lewiskat@ohsu.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19104
- 모병
- Children's Hospital of Philadelphia - Accepting Young Adult and Juvenile Patients
-
연락하다:
- CARTintake@chop.edu
- 이메일: CARTintake@chop.edu
-
수석 연구원:
- Dr. Caitlin Elgarten, MD, MSCE
-
Pittsburgh, Pennsylvania, 미국, 15261
- 모병
- UPMC Arthritis and Autoimmunity Center - Accepting Adult Patients
-
연락하다:
- Carol Oriss
- 이메일: orissca@upmc.edu
-
수석 연구원:
- Jeremy Tilstra, MD
-
Pittsburgh, Pennsylvania, 미국, 15224
- 모병
- UPMC Children's Hospital of Pittsburgh - Accepting Juvenile Patients
-
연락하다:
- Vibha Chauhan, PhD
- 전화번호: 412-692-7924
- 이메일: Vibha.chauhan@chp.edu
-
수석 연구원:
- Kathryn Torok, MD
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37232
- 모병
- Vanderbilt University Medical Center - Accepting Adult Patients
-
연락하다:
- Tofi Soneye
- 전화번호: 817-883-4730
- 이메일: tofi.soneye@vumc.org
-
-
Texas
-
Dallas, Texas, 미국, 75390
- 모병
- University of Texas Southwestern Medical Center - Accepting Juvenile Patients
-
수석 연구원:
- Samuel John, MD
-
연락하다:
- Dr. Samuel John
- 이메일: dtpteam@childrens.com
-
Houston, Texas, 미국, 77030
- 모병
- Houston Methodist Hospital - Accepting Adult Patients
-
연락하다:
- Amelia A. Nounes, MSN, RN, CCRP
- 전화번호: 346-356-3639
- 이메일: aanounes@houstonmethodist.org
-
Houston, Texas, 미국, 77030
- 모병
- University of Texas MD Anderson Cancer Center - Accepting Adult Patients
-
수석 연구원:
- Huifang (Linda) Lu, MD
-
연락하다:
- Christina Amos Briggs, BSN, RN
- 전화번호: 713-563-5076
- 이메일: cbamos@mdanderson.org
-
-
Utah
-
Salt Lake City, Utah, 미국, 84113
- 모병
- Primary Children's Hospital/University of Utah - Accepting Juvenile Patients
-
연락하다:
- Morgan Badgley - Research Coordinator
- 전화번호: 801-662-4812
- 이메일: morgan.badgley@hsc.utah.edu
-
수석 연구원:
- Aimee Ogden Hersh, MD
-
-
Washington
-
Seattle, Washington, 미국, 98105
- 모병
- Seattle Children's Research Institute - Accepting Juvenile Patients
-
연락하다:
- Dr. Susan Shenoi, MD, MS
- 전화번호: 206-987-2193
- 이메일: susan.shenoi@SeattleChildrens.org
-
수석 연구원:
- Dr. Susan Shenoi, MD, MS
-
-
Wisconsin
-
Milwaukee, Wisconsin, 미국, 53226
- 아직 모집하지 않음
- Children's Wisconsin Pediatric Rheumatology -Accepting Young Adult and Juvenile Patients
-
수석 연구원:
- Sara Sabbagh, DO
-
연락하다:
- Erin Hammelev - Research Coordinator
- 전화번호: 414-337-7064
- 이메일: ehammele@mcw.edu
-
-
-
-
-
London, 영국, WC1N 3BG
- 모병
- University College London Hospitals NHS Foundation Trust - Accepting Adult Patients
-
연락하다:
- Dr. Pedro Machado, FRCP, PhD
- 전화번호: 020 3456 7890
- 이메일: uclh.car-ttrials@nhs.net
-
수석 연구원:
- Dr. Pedro Machado, FRCP, PhD
-
London, 영국, SE5 9RS
- 모병
- Kings College Hospital NHS Foundation Trust - Accepting Adult Patients
-
연락하다:
- Rheumatology Research Team
- 전화번호: 0628 0207 848 0214
- 이메일: Kch-tr.CRDresearch@nhs.net
-
수석 연구원:
- Patrick Gordon, PhD, FRCP, MBBS
-
London, 영국, WC1N 3JH
- 모병
- Great Ormond Street Hospital for Children NHS Foundation Trust - Accepting Juvenile Patients
-
연락하다:
- Professor Despina Eleftheriou
- 전화번호: 020 7405 9200
- 이메일: Despina.Eleftheriou@gosh.nhs.uk
-
수석 연구원:
- Professor Despina Eleftheriou
-
Manchester, 영국, M13 9WL
- 모병
- Manchester Royal Infirmary - Accepting Adult Patients
-
연락하다:
- Eleni Tholouli, MD, PhD, MRCP(UK), FRCPath
- 전화번호: 01612765052
- 이메일: Eleni.Tholouli@mft.nhs.uk
-
수석 연구원:
- Eleni Tholouli, MD, PhD, MRCP(UK), FRCPath
-
Salford, 영국, M6 8HD
- 모병
- Salford Royal Hospital - Accepting Adult Patients
-
연락하다:
- Michelle Beswick
- 전화번호: 07759 136787
- 이메일: Rheumatology.Research@nca.nhs.uk
-
수석 연구원:
- Hector Chinoy, PhD, FRCP, MSc, BMBS, BMedSci
-
-
-
-
-
Roma, 이탈리아, 00165
- 모병
- Ospedale Pediatrico Bambino Gesù - Accepting Young Adult and Juvenile Patients
-
연락하다:
- Dr. Marco Becilli
- 전화번호: +39 0668592739
- 이메일: marco.becilli@opbg.net
-
수석 연구원:
- Professor Franco Locatelli
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Adult Cohorts
Inclusion Criteria:
- Age ≥18 and ≤75
- A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
- Diagnosis of DM, ASyS, or IMNM
- Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated creatine kinase (CK), DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography
- Presence of muscle weakness
Other protocol-defined criteria apply.
Exclusion Criteria:
- Contraindication to leukapheresis
- History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
- Active infection requiring medical intervention at screening
- Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections
- Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
- Significant lung or cardiac impairment
- Previous CAR T cell therapy
- Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant
Other protocol-defined criteria apply.
Juvenile Cohort
Inclusion Criteria:
- Age ≥6 and ≤17 years at enrollment
- A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
- Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated muscle enzymes, DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography
Other protocol-defined criteria apply.
Exclusion Criteria:
- Contraindication to leukapheresis
- History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
- Active infection requiring medical intervention at screening
- Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections.
- Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
- Significant lung or cardiac impairment
- Previous CAR T cell therapy
- Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant
Other protocol-defined criteria apply.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: CABA-201 Phase 1/2
DM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM. ASyS Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with ASyS. IMNM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM. JIIM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with JIIM. |
Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
다른 이름들:
|
|
실험적: CABA-201 Phase 2b - Sub-study 1
Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM and ASyS. |
Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
다른 이름들:
|
|
실험적: CABA-201 Phase 2b - Sub-study 2
Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM. |
Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Phase 1/2: Incidence and severity of adverse events (AEs)
기간: Up to 28 days after CABA-201 infusion
|
Incidence and severity of AEs |
Up to 28 days after CABA-201 infusion
|
|
Phase 2b Sub-study 1: Proportion of DM & ASyS subjects achieving at least a moderate Total Improvement Score (TIS) without any immunomodulatory medications and no or low dose of steroids
기간: Within 16 weeks
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Within 16 weeks
|
|
Phase 2b Sub-study 2: Proportion of subjects with IMNM achieving at least a minimal TIS without any immunomodulatory medications and no or low dose of steroids
기간: Within 24 weeks
|
≥20 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Within 24 weeks
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of adverse events and laboratory abnormalities
기간: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
Incidence and severity of AEs, including changes in laboratory values and vital signs |
Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
|
Pharmacodynamics (PD)
기간: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
Levels of B cells in the blood |
Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
|
Pharmacokinetics (PK)
기간: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
Levels of CABA-201-positive T cells in the blood |
Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
|
Change in disease-related biomarkers of muscle inflammation
기간: Up to 156 weeks (Phase 1/2)
|
Levels of muscle enzymes (CK, LDH, AST, ALT, and aldolase) in serum |
Up to 156 weeks (Phase 1/2)
|
|
Change in autoantibody-related biomarkers
기간: Up to 156 weeks (Phase 1/2)
|
Levels of autoantibodies from the Myositis-Specific Autoantibody Panel (e.g., MDA-5, Jo-1, and HMGCR) in the serum |
Up to 156 weeks (Phase 1/2)
|
|
Proportion of DM subjects achieving at least a moderate TIS without any immunomodulatory medications and no or low dose of steroids
기간: Week 16 (Sub-study 1)
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 16 (Sub-study 1)
|
|
Mean change from baseline on the MMT-8 in subjects with DM and ASyS without any immunomodulatory medications and no or low dose of steroids
기간: Week 16 (Sub-study 1)
|
MMT-8 measures muscle strength on a scale ranging from 0 to 150 points, where higher scores reflect greater muscle strength |
Week 16 (Sub-study 1)
|
|
Proportion of DM and ASyS subjects achieving a major TIS response without any immunomodulatory medications and no or low dose of steroids
기간: Week 16 (Sub-study 1)
|
≥60 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 16 (Sub-study 1)
|
|
Proportion of subjects with DM & ASyS achieving moderate TIS without any immunomodulatory medications on no or low dose of steroids
기간: Week 52 (Sub-study 1)
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 52 (Sub-study 1)
|
|
Proportion of subjects with DM achieving moderate TIS without any immunomodulatory medications on no or low dose of steroids
기간: Week 52 (Sub-study 1)
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 52 (Sub-study 1)
|
|
Mean change from baseline on the MMT-8 in subjects with IMNM without any immunomodulatory medications and no or low dose of steroids
기간: Week 24 (Sub-study 2)
|
MMT-8 measures muscle strength on a scale ranging from 0 to 150 points, where higher scores reflect greater muscle strength |
Week 24 (Sub-study 2)
|
|
Proportion of subjects with IMNM achieving at least minimal TIS response without immunomodulatory medications and no or low dose of steroids
기간: Week 52 (Sub-study 2)
|
≥20 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 52 (Sub-study 2)
|
공동 작업자 및 조사자
수사관
수사관
- 연구 의자: Medical Director, Cabaletta Bio
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- CAB-201-002
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .